Acurx Pharmaceuticals, Inc. Earnings Per Share (Basic)
Acurx Pharmaceuticals, Inc. (ACXP) reported Earnings Per Share (Basic) of -$0.53 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- Acurx Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.53.
- Acurx Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.62.
- Acurx Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.73.
- Acurx Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$1.23.
- Acurx Pharmaceuticals, Inc. earnings per share, basic for fiscal 2025 was -$5.32.
- Acurx Pharmaceuticals, Inc. earnings per share, basic for fiscal 2024 was -$17.45.
- Acurx Pharmaceuticals, Inc. earnings per share, basic for fiscal 2023 was -$1.15.
- Acurx Pharmaceuticals, Inc. earnings per share, basic for fiscal 2022 was -$1.12.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.53 10-Q · filed 2026-08-13 | -$1.13 10-Q · filed 2026-08-13 | -$1.81 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$2.79 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2026-03-31 | -$0.62 10-Q · filed 2026-05-11 | -$1.33 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$2.42 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$3.89 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-12-31 | -$0.73 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$1.88 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$3.50 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$5.32 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | -$1.23 10-Q · filed 2025-11-12 | -$3.01 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$5.01 10-Q · filed 2025-11-12 | -$7.86 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-06-30 | -$1.89 10-Q · filed 2026-08-13 | -$4.01 10-Q · filed 2026-08-13 | -$7.09 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$10.37 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-03-31 | -$2.15 10-Q · filed 2026-05-11 | -$0.11 10-Q · filed 2025-05-12 | -$5.34 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$8.72 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$13.74 derived: net income ÷ weighted average shares · filed 2026-08-13 | |||
| 2024-12-31 | -$3.29 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$6.73 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$11.88 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$17.45 10-K · filed 2026-03-12 | -$0.87 10-K · filed 2025-03-17 | |||
| 2024-09-30 | -$3.45 10-Q · filed 2025-11-12 | -$0.17 10-Q · filed 2024-11-12 | -$8.63 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$14.23 10-Q · filed 2025-11-12 | -$0.71 10-Q · filed 2024-11-12 | -$2.13 derived: net income ÷ weighted average shares · filed 2025-11-12 | ||
| 2024-06-30 | -$5.21 10-Q · filed 2025-08-11 | -$0.26 10-Q · filed 2024-08-08 | -$10.84 10-Q · filed 2025-08-11 | -$0.54 10-Q · filed 2024-08-08 | -$1.36 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$1.55 derived: net income ÷ weighted average shares · filed 2025-11-12 | ||
| 2024-03-31 | -$0.28 10-Q · filed 2025-05-12 | -$0.65 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$0.89 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$1.18 derived: net income ÷ weighted average shares · filed 2025-11-12 | ||||
| 2023-12-31 | -$0.37 derived: net income ÷ weighted average shares · filed 2025-03-17 | -$0.61 derived: net income ÷ weighted average shares · filed 2025-03-17 | -$0.90 derived: net income ÷ weighted average shares · filed 2025-03-17 | -$1.15 10-K · filed 2025-03-17 | ||||
| 2023-09-30 | -$0.24 10-Q · filed 2024-11-12 | -$0.52 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$0.77 10-Q · filed 2024-11-12 | -$1.05 derived: net income ÷ weighted average shares · filed 2024-11-12 | ||||
| 2023-06-30 | -$0.28 10-Q · filed 2024-08-08 | -$0.53 10-Q · filed 2024-08-08 | -$0.81 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$1.13 derived: net income ÷ weighted average shares · filed 2024-11-12 | ||||
| 2023-03-31 | -$0.25 10-Q · filed 2024-05-14 | -$0.53 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$0.85 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$1.10 derived: net income ÷ weighted average shares · filed 2024-11-12 | ||||
| 2022-12-31 | -$0.28 derived: net income ÷ weighted average shares · filed 2024-03-15 | -$0.60 derived: net income ÷ weighted average shares · filed 2024-03-15 | -$0.86 derived: net income ÷ weighted average shares · filed 2024-03-15 | -$1.12 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | -$0.32 10-Q · filed 2023-11-13 | -$0.58 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$0.84 10-Q · filed 2023-11-13 | -$1.10 derived: net income ÷ weighted average shares · filed 2023-11-13 | ||||
| 2022-06-30 | -$0.26 10-Q · filed 2023-08-11 | -$0.52 10-Q · filed 2023-08-11 | -$0.77 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$1.23 derived: net income ÷ weighted average shares · filed 2023-11-13 | ||||
| 2022-03-31 | -$0.26 10-Q · filed 2023-05-12 | -$0.52 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$0.98 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$1.49 derived: net income ÷ weighted average shares · filed 2023-11-13 | ||||
| 2021-12-31 | -$0.26 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$0.72 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$1.24 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$1.49 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | -$0.46 10-Q · filed 2022-11-10 | -$1.01 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$1.27 10-Q · filed 2022-11-10 | -$1.47 derived: net income ÷ weighted average shares · filed 2022-11-10 | ||||
| 2021-06-30 | -$0.57 10-Q · filed 2022-08-12 | -$0.79 10-Q · filed 2022-08-12 | -$0.96 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$1.18 derived: net income ÷ weighted average shares · filed 2022-11-10 | ||||
| 2021-03-31 | -$0.21 10-Q · filed 2022-05-10 | -$0.38 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$0.59 derived: net income ÷ weighted average shares · filed 2022-11-10 | |||||
| 2020-12-31 | -$0.16 derived: net income ÷ weighted average shares · filed 2022-03-16 | -$0.37 derived: net income ÷ weighted average shares · filed 2022-03-16 | -$0.74 10-K · filed 2022-03-16 | |||||
| 2020-09-30 | -$0.21 10-Q · filed 2021-11-12 | -$0.58 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |